Stock Market Reviews

Read and share opinions on LPCN (Lipocine Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Lipocine (LPCN) Reports Q3 Loss, Tops Revenue Estimates
  Nov 6, 2025
• Lipocine: Q3 Earnings Snapshot
  Nov 6, 2025
• Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025
  Nov 6, 2025
• Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®
  Nov 4, 2025
• Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)
  Sep 30, 2025
• Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference
  Sep 5, 2025
• Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025
  Aug 26, 2025
• Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025
  Aug 5, 2025
• Lipocine: Q2 Earnings Snapshot
  Aug 5, 2025
• Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression
  Jun 26, 2025
• Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025
  Jun 23, 2025
• Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada
  Jun 9, 2025
• Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology
  May 22, 2025
• Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase
  May 14, 2025
• Lipocine: Q1 Earnings Snapshot
  May 8, 2025
• Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025
  May 8, 2025
• Lipocine Announces License and Supply Agreement for TLANDO® in Brazil
  May 6, 2025
• Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154
  Mar 26, 2025